- Home
- BIIB vs TRMB Comparison
BIIB vs TRMB Comparison
Compare BIIB & TRMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- TRMB
- Stock Information
- Founded
- BIIB 1978
- TRMB 1978
- Country
- BIIB United States
- TRMB United States
- Employees
- BIIB N/A
- TRMB N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- TRMB Industrial Machinery/Components
- Sector
- BIIB Health Care
- TRMB Industrials
- Exchange
- BIIB Nasdaq
- TRMB Nasdaq
- Market Cap
- BIIB 18.7B
- TRMB 19.3B
- IPO Year
- BIIB 1991
- TRMB 1990
- Fundamental
- Price
- BIIB $144.56
- TRMB $81.36
- Analyst Decision
- BIIB Buy
- TRMB Buy
- Analyst Count
- BIIB 27
- TRMB 6
- Target Price
- BIIB $188.09
- TRMB $90.33
- AVG Volume (30 Days)
- BIIB 1.5M
- TRMB 1.3M
- Earning Date
- BIIB 10-29-2025
- TRMB 11-05-2025
- Dividend Yield
- BIIB N/A
- TRMB N/A
- EPS Growth
- BIIB 31.67
- TRMB N/A
- EPS
- BIIB 10.45
- TRMB 1.18
- Revenue
- BIIB $9,997,000,000.00
- TRMB $3,575,500,000.00
- Revenue This Year
- BIIB $2.00
- TRMB N/A
- Revenue Next Year
- BIIB N/A
- TRMB $6.77
- P/E Ratio
- BIIB $13.83
- TRMB $67.76
- Revenue Growth
- BIIB 3.36
- TRMB N/A
- 52 Week Low
- BIIB $110.04
- TRMB $52.91
- 52 Week High
- BIIB $204.18
- TRMB $87.50
- Technical
- Relative Strength Index (RSI)
- BIIB 58.75
- TRMB 51.21
- Support Level
- BIIB $141.12
- TRMB $78.77
- Resistance Level
- BIIB $147.23
- TRMB $83.68
- Average True Range (ATR)
- BIIB 4.56
- TRMB 1.66
- MACD
- BIIB 0.11
- TRMB 0.02
- Stochastic Oscillator
- BIIB 67.64
- TRMB 60.17
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About TRMB Trimble Inc.
Trimble Inc is a technology solutions provider that enables office and mobile professionals to connect their workflows and asset lifecycles to drive a more productive, sustainable future. The company has three reportable segments: Architects, Engineers, Construction, and Owners (AECO). This segment provides software solutions that sell through a direct channel to customers in the construction industry. Field Systems. This segment provides hardware and associated software solutions that sell through dealer partner channels. Transportation and Logistics (T&L). This segment provides solutions for customers working in long-haul trucking and freight shipping markets.